[1] |
PANG Shengfeng, ZHANG Jing, WU Ningning, LI Ru, CAO Jun, HE Shenghu.
Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1004-1009.
|
[2] |
WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming.
Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
|
[3] |
LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian.
Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
|
[4] |
DENG Yifan, HE Shenghu, WANG Daxin, DAI Chengye, XU Xiaoting, ZHANG Jing.
Clinical study of effect of ezetimibe combined with statins on residual lipoprotein cholesterol and MACE events in patients undergoing emergency intervention with acute coronary syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1048-1052.
|
[5] |
XIA Chunyong, ZHANG Zuowen, HE Xiaoyan, LIU Jie, LI Xiaoya, CHANG Qiuhong, QIN Lijuan, CAO Zhenming, DING Ling.
Correlation between CYP2C19 gene polymorphism and individualized medication in patients with ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 318-323.
|
[6] |
YUAN Zhen, CHEN Bilian.
Review of bleeding events in clinical studies of clopidogrel
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 341-349.
|
[7] |
XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang.
Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
|
[8] |
PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie.
Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
|
[9] |
LI Jiadan,LU Chen.
Synergistic effects of Cortex Mori alkaloids combined with Simvastatin in rats with hyperlipidaemia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 278-284.
|
[10] |
SUN Qing, SUN Jianfang, LI Li, CHANG Huichao, ZHOU Quan.
Effects of Wuzhi capsule on the pharmacokinetics of simvastatin and its metabolite simvastatin acid in rats
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1242-1249.
|
[11] |
YANG Rui, LIU Hui, CHEN Zeheng, QI Tingting,ZHANG Zanling, QU Qiang.
Clinical pharmacists use CYP2C19 genotyping test to guide individual medication therapy of Clopidogrel and to evaluate the efficacy of treatment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 938-943.
|
[12] |
ZHANG Qian, FU Hong, CHEN Jinjin, ZHU Yubing.
Research progress of IL33/ST2 in acute coronary syndrome
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1075-1080.
|
[13] |
WANG Weiyu, YU Hao.
Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
|
[14] |
ZHANG Xia, KE Yong-sheng.
Clinical research of new type P2Y12 Receptor inhibitor ticagrelor
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(4): 459-464.
|
[15] |
YANG Yong-ge, ZHANG Mei, JIANG Nan, SONG Li-xue, XU Xue-ting, DI Xiao-hui, XU Lin, XU Juan,ZHAO Gang-tao.
Bioequivalence of clopidogrel hydrogen sulfate tablets in healthy Chinese volunteers
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 38-43.
|